Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey Alan Sosman, Kevin B. Kim, Lynn Mara Schuchter et al. · New England Journal of Medicine · 2012
BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600-mutant metastatic melanoma in a phase 1 trial and improved overall survival in a phase 3 trial. METHODS: We designed a multicenter phase 2 trial of vemurafenib in patients with previously treated BRAF V600-mutant metastatic melanoma to investigate the efficacy of vemurafenib with respect to overall response rate (percentage of treated patients with a tumor response), duration of response, and overall survival. The primary end point was the overall response rate as ascertained by the independent review committee; overall survival was a secondary end point. RESULTS: A total of 132 patients had a median follow-up of 12.9 months (range, 0.6 to 20.1). The confirmed overall response rate was 53% (95% confidence interval [CI], 44 to 62; 6% with a complete response and 47% with a partial response), the median duration of response was 6.7 months (95% CI, 5.6 to 8.6), and the median progression-free survival was 6.8 months (95% CI, 5.6 to 8.1). Primary progression was observed in only 14% of patients. Some patients had a response after receiving vemurafenib for more than 6 months. The median overall survival was 15.9 months (95% CI, 11.6 to 18.3). The most common adverse events were grade 1 or 2 arthralgia, rash, photosensitivity, fatigue, and alopecia. Cutaneous squamous-cell carcinomas (the majority, keratoacanthoma type) were diagnosed in 26% of patients. CONCLUSIONS: Vemurafenib induces clinical responses in more than half of patients with previously treated BRAF V600-mutant metastatic melanoma. In this study with a long follow-up, the median overall survival was approximately 16 months. (Funded by Hoffmann-La Roche; ClinicalTrials.gov number, NCT00949702.).
Cited by 2,158 works. doi:10.1056/nejmoa1112302 Open-access PDF
Authors
- Jeffrey Alan Sosman
- Kevin B. Kim
- Lynn Mara Schuchter
- Rene C. Gonzalez
- Anna C. Pavlick
- Jeffrey S. Weber
- Grant A. McArthur
- Thomas E. Hutson
- Stergios J. Moschos
- Keith T. Flaherty
- Peter Hersey
- Richard F. Kefford
- Donald P. Lawrence
- Igor J. Puzanov
- Karl D. Lewis
- Ravi K. Amaravadi
- Bartosz Chmielowski
- H. Jeffrey Lawrence
- Yu Shyr
- Fei Ye
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Mutations of the BRAF gene in human cancer
- THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- A Confidence Interval for the Median Survival Time
- High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993